• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients.紫杉醇在晚期胃癌患者恶性腹水中的药代动力学研究。
World J Gastroenterol. 2006 Mar 7;12(9):1412-5. doi: 10.3748/wjg.v12.i9.1412.
2
[A case of advanced gastric cancer treated with weekly paclitaxel with measurement of paclitaxel concentrations in blood and ascites].[1例晚期胃癌采用每周紫杉醇治疗并检测血液和腹水中紫杉醇浓度的病例]
Gan To Kagaku Ryoho. 2003 Oct;30(10):1529-31.
3
Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer.评估治疗不可测量病变的胃癌恶性腹水的临床获益反应:紫杉醇治疗晚期/复发性胃癌继发恶性腹水的多中心 II 期试验。
Gastric Cancer. 2011 Mar;14(1):81-90. doi: 10.1007/s10120-011-0016-6. Epub 2011 Feb 17.
4
[A case of advanced gastric cancer with malignant ascites responding to weekly paclitaxel therapy].[一例晚期胃癌伴恶性腹水对每周紫杉醇治疗有效的病例]
Gan To Kagaku Ryoho. 2006 Nov;33(11):1637-40.
5
Pharmacokinetics of docetaxel in gastric cancer patients with malignant ascites.胃癌伴恶性腹水患者多西紫杉醇的药代动力学。
Cancer Chemother Pharmacol. 2013 Mar;71(3):727-31. doi: 10.1007/s00280-012-2066-9. Epub 2013 Jan 12.
6
Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan.日本晚期或复发性胃癌患者每周紫杉醇给药剂量的药代动力学研究。
Gastric Cancer. 2007;10(1):52-7. doi: 10.1007/s10120-006-0411-6. Epub 2007 Feb 23.
7
A phase II clinical trial to evaluate the effect of paclitaxel in patients with ascites caused by advanced or recurrent gastric carcinoma: a new concept of clinical benefit response for non-measurable type of gastric cancer.一项评估紫杉醇对晚期或复发性胃癌所致腹水患者疗效的II期临床试验:不可测量型胃癌临床获益反应的新概念。
Jpn J Clin Oncol. 2003 May;33(5):238-40. doi: 10.1093/jjco/hyg048.
8
[Recurrent ovarian cancer with cancer peritonitis treated with weekly paclitaxel infusion--a clinicopharmacological study].
Gan To Kagaku Ryoho. 2004 Mar;31(3):449-51.
9
A case of scirrhous gastric cancer with peritonitis carcinomatosa controlled by TS-1 + paclitaxel for 36 mo after diagnosis.一例诊断后接受替吉奥(TS-1)联合紫杉醇治疗、癌性腹膜炎得到控制的硬癌型胃癌患者,生存期达36个月。
World J Gastroenterol. 2007 Jan 21;13(3):470-3. doi: 10.3748/wjg.v13.i3.470.
10
[A case of recurrent gastric cancer with malignant ascites responding dramatically to chemotherapy with paclitaxel infused systemically and intraperitoneally].[一例复发性胃癌伴恶性腹水患者经全身及腹腔内注射紫杉醇化疗后疗效显著]
Gan To Kagaku Ryoho. 2004 Nov;31(12):2027-30.

引用本文的文献

1
Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis.全身化疗联合PD - 1抑制剂与静脉或腹腔注射贝伐单抗治疗伴腹膜转移的胃癌的安全性和有效性。
BMC Cancer. 2025 Jun 6;25(1):1010. doi: 10.1186/s12885-025-14206-9.
2
Advances in the treatment of malignant ascites in China.中国恶性腹水治疗的进展。
Support Care Cancer. 2024 Jan 11;32(2):97. doi: 10.1007/s00520-023-08299-w.
3
Distribution of therapeutic monoclonal antibodies into ascites in advanced gastric cancer patients with peritoneal metastasis: case reports and literature review.治疗性单克隆抗体在晚期胃癌伴腹膜转移患者腹腔内的分布:病例报告及文献复习。
Cancer Chemother Pharmacol. 2022 Nov;90(5):421-426. doi: 10.1007/s00280-022-04479-3. Epub 2022 Sep 30.
4
Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer.静脉或腹腔注射紫杉醇联合mFOLFOX6对比mFOLFOX6作为晚期胃癌一线治疗的2期随机对照试验
Front Oncol. 2022 Sep 7;12:850242. doi: 10.3389/fonc.2022.850242. eCollection 2022.
5
Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study).静脉和腹腔紫杉醇联合 S-1 与吉西他滨联合白蛋白紫杉醇治疗伴有腹膜转移的胰腺导管腺癌的随机 III 期试验(SP 研究)。
Trials. 2022 Feb 5;23(1):119. doi: 10.1186/s13063-022-06049-7.
6
Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G.氟尿嘧啶类药物联合紫杉醇治疗胃癌腹膜转移患者的临床意义:JCOG1108/WJOG7312G 的事后研究。
Cancer Med. 2021 Nov;10(21):7673-7682. doi: 10.1002/cam4.4303. Epub 2021 Oct 16.
7
Clinical Characteristics and Therapeutic Outcomes of Metastatic Peritoneal Carcinomatosis in Non-Small-Cell Lung Cancer.非小细胞肺癌转移性腹膜癌的临床特征与治疗结果
Cancer Manag Res. 2021 Sep 29;13:7497-7503. doi: 10.2147/CMAR.S330103. eCollection 2021.
8
Current status of conversion surgery for stage IV gastric cancer.IV 期胃癌转化手术的现状。
Surg Today. 2021 Nov;51(11):1736-1754. doi: 10.1007/s00595-020-02222-0. Epub 2021 Jan 23.
9
Paclitaxel-coated drug-eluting balloon for pulmonary vein stenosis after repair of total anomalous pulmonary venous return with asplenia.用于无脾综合征完全性肺静脉异位引流修复术后肺静脉狭窄的紫杉醇涂层药物洗脱球囊
J Cardiol Cases. 2020 Jun 2;22(3):107-109. doi: 10.1016/j.jccase.2020.05.008. eCollection 2020 Sep.
10
Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis.多西他赛+奥沙利铂+S-1与奥沙利铂+S-1作为局部进展期胃癌新辅助化疗的比较:一项倾向评分匹配分析
Cancer Manag Res. 2020 Jul 30;12:6641-6653. doi: 10.2147/CMAR.S258360. eCollection 2020.

本文引用的文献

1
[A case of metastatic gastric cancer responding to weekly administration of paclitaxel as a second-line therapy].[1例转移性胃癌对每周一次紫杉醇二线治疗有反应]
Gan To Kagaku Ryoho. 2003 Jan;30(1):129-32.
2
[Effective weekly paclitaxel administration for gastric cancer with malignant ascites--a case report].[每周一次紫杉醇有效治疗伴有恶性腹水的胃癌——一例报告]
Gan To Kagaku Ryoho. 2002 Sep;29(9):1643-6.
3
Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions.采用三小时输注紫杉醇治疗晚期胃癌并进行短程预处理以预防紫杉醇相关过敏反应的II期试验。
Ann Oncol. 2001 Aug;12(8):1133-7. doi: 10.1023/a:1011680507956.
4
Phase II trial of outpatient schedule of paclitaxel in patients with previously untreated metastatic, measurable adenocarcinoma of the stomach.
Jpn J Clin Oncol. 2001 Jun;31(6):275-8. doi: 10.1093/jjco/hye060.
5
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.一项针对晚期胃癌患者的II期研究,该研究采用每周一次、24小时持续输注紫杉醇、5-氟尿嘧啶、亚叶酸钙和顺铂的治疗方案。
Br J Cancer. 2000 Aug;83(4):458-62. doi: 10.1054/bjoc.2000.1295.
6
Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen.
Am J Clin Oncol. 1999 Dec;22(6):580-6. doi: 10.1097/00000421-199912000-00008.
7
Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas.
Cancer. 1999 Jun 1;85(11):2347-51. doi: 10.1002/(sici)1097-0142(19990601)85:11<2347::aid-cncr8>3.0.co;2-8.
8
Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma.紫杉醇、5-氟尿嘧啶和顺铂联合化疗治疗晚期胃癌
Cancer. 1999 Jan 15;85(2):295-301.
9
Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.
J Clin Oncol. 1998 Aug;16(8):2620-4. doi: 10.1200/JCO.1998.16.8.2620.
10
Development of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids.
Cancer. 1997 Mar 1;79(5):1022-30. doi: 10.1002/(sici)1097-0142(19970301)79:5<1022::aid-cncr20>3.0.co;2-2.

紫杉醇在晚期胃癌患者恶性腹水中的药代动力学研究。

Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients.

作者信息

Kobayashi Michiya, Sakamoto Junichi, Namikawa Tsutomu, Okamoto Ken, Okabayashi Takehiro, Ichikawa Kengo, Araki Keijiro

机构信息

Department of Tumor Surgery, Kochi Medical School, Kohasu, Nankoku 783-8505, Japan.

出版信息

World J Gastroenterol. 2006 Mar 7;12(9):1412-5. doi: 10.3748/wjg.v12.i9.1412.

DOI:10.3748/wjg.v12.i9.1412
PMID:16552811
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4124320/
Abstract

AIM

To examine the paclitaxel concentrations in plasma and ascites after its intravenous administration in patients with ascites due to peritonitis carcinomatosa resulting from advanced gastric cancer.

METHODS

Two patients with ascites due to peritonitis carcinomatosa resulting from gastric cancer were included in this study. The paclitaxel concentrations in plasma and ascites were investigated for 72 h in case 1 and 168 h in case 2 after intravenous administration.

RESULTS

The paclitaxel concentration in plasma peaked immediately after administration, followed by rapid decrease below the threshold value of 0.1 micromol (85 ng/mL) within 24 h. In contrast,the paclitaxel concentration in ascites increased gradually for 24 h after administration to a level consistent with the level found in plasma. After 24 h the level of paclitaxel in ascites and plasma became similar, with the optimal level being maintained up to 72 h following administration.

CONCLUSION

The concentration of paclitaxel in ascites is maintained within the optimal level for the treatment of cancer cells for up to 72 h after intravenous administration. Paclitaxel is a promising drug for the treatment of malignant ascites of gastric cancer.

摘要

目的

研究晚期胃癌导致的癌性腹膜炎腹水患者静脉注射紫杉醇后血浆和腹水中紫杉醇的浓度。

方法

本研究纳入两名因胃癌导致癌性腹膜炎腹水的患者。在病例1中静脉注射后72小时以及病例2中静脉注射后168小时,对血浆和腹水中的紫杉醇浓度进行研究。

结果

血浆中紫杉醇浓度在给药后立即达到峰值,随后在24小时内迅速降至低于0.1微摩尔(85纳克/毫升)的阈值。相比之下,腹水中紫杉醇浓度在给药后24小时内逐渐升高至与血浆中浓度一致的水平。24小时后,腹水和血浆中的紫杉醇水平变得相似,给药后长达72小时维持在最佳水平。

结论

静脉注射紫杉醇后,腹水中紫杉醇浓度在长达72小时内维持在治疗癌细胞的最佳水平。紫杉醇是治疗胃癌恶性腹水的一种有前景的药物。